A Small Molecule That In Vitro Neutralizes Infection of SARS-CoV-2 and Its Most Infectious Variants, Delta, and Omicron

• Published in: Biomedicines Vol. 11; no. 3; p. 916
• Main Authors: Reyes-Alcaraz, Arfaxad, Qasim, Hanan, Merlinsky, Elizabeth, Fox, Glenn, Islam, Tasneem, Medina, Bryan, Schwartz, Robert J, Craft, Jr, John W, McConnell, Bradley K
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-03-2023; MDPI
• Subjects: Antiviral agents; Brief Report; Coronaviruses; COVID-19; COVID-19 vaccines; Delta; Disease transmission; Infections; Omicron; Plasmids; Proteins; SARS-CoV-2 spike protein; Severe acute respiratory syndrome coronavirus 2; Viruses; United States; United States > US; COVID-19; SARS-CoV-2 spike protein; Omicron; Delta
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines11030916

The COVID-19 pandemic has underscored the urgent need to develop highly potent and safe medications that are complementary to the role of vaccines. Specifically, it has exhibited the need for orally bioavailable broad-spectrum antivirals that are able to be quickly deployed against newly emerging viral pathogens. The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and its variants Delta and Omicron are still a major threat to patients of all ages. In this brief report, we describe that the small molecule CD04872SC was able to neutralize SARS-CoV2 infection with a half-maximal effective concentration (EC50) = 248 μM. Serendipitously, we also were able to observe that CD04872SC inhibited the infection of the SARS-CoV-2 variants; Delta (EC50 = 152 μM) and Omicron (EC50 = 308 μM). These properties may define CD04872SC as a potential broad-spectrum candidate lead for the development of treatments for COVID-19.